Drug Use Investigation for XYZAL®

GlaxoSmithKline10,728 enrolled

Overview

This post-marketing surveillance study (PMS) is conducted to collect safety and efficacy data among subjects with allergic rhinitis, urticaria, eczema, dermatitis, skin irritation, prurigo or pruritus cutaneous who have never been treated with levocetirizine tablets before.

Study Type

OBSERVATIONAL

Enrollment

10,728

Conditions

Rhinitis, Allergic, Perennial and Seasonal

Interventions

LevocetirizineDRUG

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Must be the first time for taking levocetirizine tablet Exclusion Criteria: * As this is PMS study, there are no exclusion criteria.

Outcomes

Primary Outcomes

The number of adverse events in Japanese subjects treated with levocetirizine tablets

Time frame: 4 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.